US OptionsDetailed Quotes
MU241213C93000
- 9.04
- +3.84+73.85%
15min DelayClose Dec 13 16:00 ET
10.00High7.35Low
10.00Open5.20Pre Close6 Volume170 Open Interest93.00Strike Price4.94KTurnover4175.89%IV-0.45%PremiumDec 13, 2024Expiry Date9.50Intrinsic Value100Multiplier0DDays to Expiry0.00Extrinsic Value100Contract SizeAmericanOptions Type0.9426Delta0.0181Gamma10.57Leverage Ratio-435.3481Theta0.0000Rho9.96Eff Leverage0.0002Vega
Micron Technology Stock Discussion
Sign in to post a comment
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drugs and need additional lowering. Over 71 ...
+2
3
1
1
This unique biotech $Esperion Therapeutics (ESPR.US)$ Esperion has the only FDA approved statin alternative drugs NEXLIZET & NEXLETOL for Primary Prevention, Statins are a class of prescription drugs that help lower cholesterol levels. They are the most common treatment for high cholesterol, an estimated 21 Million Americans are Statin intolerant and or maxed out on Statin drug...
+2
1
The market was mixed Friday, with a tech climb bringing the Nasdaq to fresh highs. The S&P 500 was dead flat Friday, while the Dow fell.
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ closed flat the $Dow Jones Industrial Average (.DJI.US)$ fell 0.20%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.12%.
MACRO
In macro, trade index numbers arrived from the U.S. Department of Labor. Prices, both export and import came in ab...
Just past 4 pm ET the $S&P 500 Index (.SPX.US)$ closed flat the $Dow Jones Industrial Average (.DJI.US)$ fell 0.20%, and the $Nasdaq Composite Index (.IXIC.US)$ climbed 0.12%.
MACRO
In macro, trade index numbers arrived from the U.S. Department of Labor. Prices, both export and import came in ab...
40
6
5
High-end chip designer $Micron Technology (MU.US)$ will report earnings next Wednesday (Dec. 18), with analysts looking for about 84% in year-over-year revenue growth – representing what would be the third straight quarter of 80%+ annual sales gains. Let’s see what MU’s fundamental and technical analysis say heading into the report.
Micron's Fundamental Analysis
MU management has previously guided its fiscal Q1 results to $1.74 in adjusted...
Micron's Fundamental Analysis
MU management has previously guided its fiscal Q1 results to $1.74 in adjusted...
9
1
$Micron Technology (MU.US)$ does anyone know what major investor or hedge fund is buying the stock and then dumping the stock on a daily cycle? it appears to me the inflow and outflow of money is not logical. need help to understand
2
3
$Micron Technology (MU.US)$ classic open high close low again.
2
2
5
5
![[undefined]](https://static.moomoo.com/nnq/emoji/static/image/default/default-black.png?imageMogr2/thumbnail/36x36 "undefined"){kind=small}
No comment yet
10xStockPicks OP : This is the correctly edited research report. Previous article has a few typos. Special thanks to Fund manager John for his notes. Please do your own research. I firmly believe ESPR will be a solid bet.